PMID: 9450813Feb 5, 1998Paper

Megakaryocyte progenitors derived from bone marrow or G-CSF-mobilized peripheral blood CD34 cells show a distinct phenotype and responsiveness to interleukin-3 (IL-3) and PEG-recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF)

British Journal of Haematology
L CataniS Tura

Abstract

In the present study we investigated the proliferative response of megakaryocyte progenitor cells (CFU-MK) derived from peripheral blood stem cell (PBSC) collections of patients with haematological malignancies and normal donors. Highly purified CD34+ cells and mononuclear cell fractions were assayed in the presence of recombinant interleukin-3 (IL-3) and pegylated-recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF), alone or in combination, and megakaryocyte colony formation was evaluated in the plasma clot. In comparison, steady-state bone marrow samples from normal donors were highly enriched in CD34+ cells and tested with the cytokines studied. Our results showed that IL-3 was able to stimulate CFU-MK colony formation from bone marrow and peripheral blood CD34+ cells. Similarly, PEG-rHuMGDF stimulated, in a dose-response manner, CD34+ cells from the bone marrow. However, normal mobilized peripheral blood CD34+ cells were not induced to generate CFU-MK colonies by PEG-rHuMGDE The same lack of response was observed when patients peripheral blood CD34+ cells primed with chemotherapy plus G-CSF or with G-CSF alone were assessed. In contrast, PEG-rHuMGDF stimulated CFU-MK growth when mononuclear cells, ei...Continue Reading

References

Jul 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P E PostmusE G de Vries
Jan 1, 1991·International Journal of Cell Cloning·G ZauliG P Bagnara
Jun 1, 1986·The Journal of Clinical Investigation·H H YangR Hoffman
Apr 11, 1995·Proceedings of the National Academy of Sciences of the United States of America·K KaushanskyC Lofton-Day
Mar 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J WeberD Cole
Jul 1, 1993·Stem Cells·P R Hénon, M Becker
Sep 1, 1994·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·P HyllandP L Lutz
Oct 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M VoseJ O Armitage
Jun 16, 1994·Nature·F WendlingW Vainchenker
Nov 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R Hoffman
May 1, 1996·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·A O Williams, A D Knapton
May 1, 1996·Bone·P G Genever, I R Dickson
Nov 1, 1995·Critical Reviews in Oncology/hematology·G Zauli, L Catani
Jan 1, 1997·Critical Reviews in Oncology/hematology·G M Clinton, W Hua

❮ Previous
Next ❯

Citations

Mar 21, 2006·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Sule Mine BakanayOsman Ilhan
Dec 22, 1999·American Journal of Hematology·D S KyriakouG D Eliopoulos
Nov 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ayalew Tefferi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.